AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CBIO

Scalzo Richard William sold $10K of CBIO

Scalzo Richard William (Chief Financial Officer) sold 568 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.90 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Scalzo Richard William
Published Sep 18, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
high confidence
Mentioned
$CBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

The CFO's sale is modest and executed via a pre‑arranged plan, suggesting no urgent market‑moving information.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases that may outweigh the impact of this small sale.

Relevance 2/10Novelty 3/10Timing: filed Sep 18, transaction dated Sep 16

Background

Form 4 filing discloses insider transactions; such filings are routine and often low‑impact.

Company-level read

Ticker impact

$CBIONeutralHigh confidence
Context

CFO Richard Scalzo sold 568 shares for $10,167 via a 10b5-1 plan, reducing his stake to 19,730 shares.

Expected impact

No material price movement expected; possible slight short‑term pressure.

Evidence & confidence

The sale amount is small relative to market cap and typical insider activity; market likely discounts it.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; limited to CBIO shareholders.

Global

None

Counterpoint

What could challenge this read

If the CFO is reducing exposure, it could signal concerns about near‑term performance.

Key entities

  • Company
    Crescent Biopharma, Inc.

    Biopharma company listed on NASDAQ under ticker CBIO.

  • Executive
    Richard William Scalzo

    Chief Financial Officer of Crescent Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

JUL 30
$CBIOMed

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treate

SEC EDGAR 8-K4 min
JUL 14
$CBIOLow

CRESCENT BIOPHARMA, INC. (CBIO): Results of Operations and Financial Condition

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. cbio-20260714 0001253689 false 0001253689 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________________________________________________ FORM 8-K ______________________________________

SEC EDGAR 8-K1 min